Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 758 matching trials from the live ClinicalTrials.gov search.
Conditions
Hodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Conditions
Rabies
Interventions
Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Pembroke Pines, Florida • South Miami, Florida • Boise, Idaho + 2 more
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

Electromyography to Diagnose Neuromuscular Disorders

NCT00004553
Conditions
Healthy, Neuromuscular Disease, Postpoliomyelitis Syndrome
Interventions
Electromyography
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Long COVID
Interventions
WATER+CT, Usual Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
Interventions
Ruconest
Drug
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Centennial, Colorado
Conditions
Covid19, Viral Syndrome
Interventions
Treadmill Exercise, Concentrated Oxygen, Concentrated Air
Other
Lead sponsor
Noah Greenspan
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2Phase 3 Interventional Results available

Fluvoxamine for Long COVID-19

NCT05874037
Conditions
Long COVID
Interventions
Fluvoxamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Long COVID
Interventions
wait-list, chiropractic adjustments
Other · Procedure
Lead sponsor
Life University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Enhance Wellness for Individuals With Long-Term Physical Disabilities

NCT02815878
Conditions
Multiple Sclerosis, Muscular Dystrophy, Post-polio Syndrome, Spinal Cord Injury
Interventions
Enhance Wellness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Breast Cancer Related Lymphedema, Covid19
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Posttraumatic Stress Disorder
Interventions
Virtual Reality Exposure Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, HER2-negative Breast Cancer, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Male Breast Cancer, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Colon Cancer, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Rectal Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Rectal Cancer, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, B Lymphoblastic Leukemia/Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Hepatosplenic T-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mycosis Fungoides, Nasal Type Extranodal NK/T-Cell Lymphoma, Nodal Marginal Zone Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Effusion Lymphoma, Sezary Syndrome, Splenic Marginal Zone Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, T Lymphoblastic Leukemia/Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Salvia hispanica Seed
Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Dried Blood Spot Testing of CMV Detection in HCT Recipients

NCT03910478
Conditions
Cytomegalovirus Infection
Interventions
DBS Self-Collection Kit, Standard Control Strategy
Device · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 99 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Houston, Texas + 1 more
Completed Not applicable Interventional

Vagal Approaches on Long COVID-19

NCT07190105
Conditions
Long COVID Symptoms
Interventions
Sonocea Sonic Augmentation Technology (SAT), Truvaga Electrical Vagus Nerve Stimulator
Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Frederick, Maryland
Conditions
Post-Coronavirus Disease 19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland